MVM Partners LLP Closes MVM V

BOSTON & LONDON–(BUSINESS WIRE)–MVM Partners today announced the closing of a $325 million healthcare fund, MVM V.

MVM has been investing in high growth healthcare businesses since 1997 and this latest fund, MVM V, will continue this broad, global, investment remit with investments in medical technology, pharmaceuticals, biotechnology, diagnostics, life science tools, and digital health in both private deals and quoted companies. Typical projected investment in each company is $20 to $40 million, but with capacity for larger investments.

In aggregate, MVM has raised investment vehicles totaling over $1 billion which are managed from offices in Boston and London. For more information visit www.mvm.com.

This press release, together with any information or documents accompanying it, is issued by MVM Partners LLP, which is authorised and regulated in the UK by the Financial Conduct Authority.

This document does not constitute an offer or invitation to subscribe or purchase limited partnership interests. Any investment in MVM V LP will be made solely on the basis of the private placement memorandum issued in connection therewith and the limited partnership agreement and associated documentation.

Contacts

MVM Partners LLP
Dr Stephen Reeders

sr@mvm.com

Dr Eric Bednarski

eb@mvm.com

Mr Thomas Casdagli

tc@mvm.com

Staff

Recent Posts

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)…

2 hours ago

Early Data Shows that Coverage of Saliva-Based Screenings Drives Improved Patient Engagement and Treatment Plan Acceptance

BOSTON, Dec. 10, 2025 /PRNewswire/ -- A new enhanced benefit program by Delta Dental of Massachusetts (DDMA),…

4 hours ago

Robert Half Selected by Newsweek as One of America’s Most Responsible Companies 2026

MENLO PARK, Calif., Dec. 10, 2025 /PRNewswire/ -- Global talent solutions and business consulting firm…

4 hours ago

Azenta Authorizes $250 Million Share Repurchase Program

BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its…

4 hours ago

SkinSight™ AI by ModuleMD: Smarter Skin Analysis, Faster Clinical Decisions

GRAND BLANC, Mich., Dec. 10, 2025 /PRNewswire/ -- ModuleMD, ranked as one of America's fastest-growing…

4 hours ago